E1 ReplicatedModerate confidencePEM unclearRCTPeer-reviewedMachine draft
Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: a randomized controlled trial.
Fagermoen, Even, Sulheim, Dag, Winger, Anette et al. · BMC pediatrics · 2015 · DOI
Quick Summary
This study tested whether a low-dose blood pressure medication called clonidine could help adolescents with ME/CFS, particularly those experiencing dizziness when standing up. Researchers found that clonidine did reduce certain stress hormones in the blood and improved some measurements of heart rhythm control while lying down, but it did not relieve the actual symptoms of dizziness or improve heart function during positional changes.
Why It Matters
Orthostatic intolerance is a hallmark feature of ME/CFS that severely limits activity in many adolescents. This study directly addresses whether targeting sympathetic overactivity—a proposed mechanism in the condition—can provide clinical benefit, informing whether autonomic-directed therapies warrant further investigation or require different approaches.
Observed Findings
- Clonidine lowered plasma norepinephrine by 205 pmol/L (p=0.05) and urine norepinephrine/creatinine ratio by 3.9 nmol/mmol (p=0.002) at 8 weeks.
- During supine rest, the clonidine group showed higher low-frequency heart rate variability (LF-HRV) with a ratio of 1.4 (p=0.007).
- Supine standard deviation of all RR-intervals (SDNN) was 12.0 ms higher in the clonidine group (p=0.05).
- No significant differences in cardiovascular variables were observed during 20° head-up tilt testing between groups.
- Orthostatic intolerance symptoms did not improve in either group during the 9-week intervention period.
Inferred Conclusions
- Low-dose clonidine effectively reduces catecholamine levels in adolescents with CFS.
- Biochemical and some resting autonomic improvements from clonidine do not translate to clinical symptom relief, particularly for orthostatic intolerance.
- Reduction of sympathetic tone alone may be insufficient to address the underlying mechanisms of orthostatic intolerance in CFS.
Remaining Questions
- Why do biochemical improvements in catecholamine levels and supine heart rate variability not correlate with symptomatic improvement?
- Would combination pharmacological approaches or different adrenergic targets be more effective than single-agent clonidine?
What This Study Does Not Prove
This study does not prove that autonomic dysfunction is not central to ME/CFS pathophysiology, only that reducing catecholamines via clonidine does not clinically improve orthostatic symptoms in this population. The lack of symptom improvement does not exclude other autonomic interventions or combination approaches as potentially beneficial. Additionally, findings in adolescents may not generalize to adults with ME/CFS.
Tags
Symptom:Orthostatic IntoleranceFatigue
Biomarker:Blood Biomarker
Phenotype:Pediatric
Method Flag:Weak Case DefinitionSmall Sample
Metadata
- DOI
- 10.1186/s12887-015-0428-2
- PMID
- 26357864
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →